Aytu Biopharma (AYTU) Non Operating Investment Income (2016 - 2017)
Aytu Biopharma (AYTU) posted quarterly Non Operating Investment Income of -$292455.0 for Q2 2017, little changed quarter-over-quarter from -$292455.0 in Q1 2017.
Aytu Biopharma (AYTU) Non Operating Investment Income (2016 - 2017) Analysis & Trends
Aytu Biopharma (AYTU) has reported Non Operating Investment Income for 2 consecutive years, with -$292455.0 the latest figure, recorded in Q2 2017.
- In Q2 2017, Non Operating Investment Income changed N/A year-over-year to -$292455.0; the TTM figure through Jun 2017 stood at -$353974.0 (changed N/A YoY), while the FY2017 annual figure was -$61519.0, up 93.67% from the prior year.
- Non Operating Investment Income steadied at -$292455.0 in Q2 2017 per AYTU's latest filing, from -$292455.0 in the prior quarter.
- Across five years, Non Operating Investment Income topped out at $728100.0 in Q3 2016 and bottomed at -$497164.0 in Q4 2016.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Non Operating Investment Income (Qtr) |
|---|---|---|---|---|---|
| 1 | Haleon | 43.87 Bn | 42.91 Bn | - | - |
| 2 | Teva Pharmaceutical Industries | 43.00 Bn | 39.35 Bn | 2.15 Bn | - |
| 3 | Zoetis | 31.59 Bn | 29.92 Bn | 1.05 Bn | - |
| 4 | Takeda Pharmaceutical | 28.63 Bn | 22.83 Bn | 5.10 Bn | - |
| 5 | United Therapeutics | 22.15 Bn | 19.49 Bn | 683.80 Mn | - |
| 6 | Viatris | 18.74 Bn | 17.85 Bn | 1.46 Bn | - |
| 7 | Neurocrine Biosciences | 15.55 Bn | 15.16 Bn | 935.80 Mn | - |
| 8 | Elanco Animal Health | 11.75 Bn | 11.22 Bn | 798.00 Mn | - |
| 9 | Dr Reddys Laboratories | 10.12 Bn | 9.96 Bn | - | - |
| 10 | Aytu Biopharma | 24.60 Mn | -2.12 Mn | 7.60 Mn | - |
Historic Data
Download Data| Date | Value |
|---|---|
| Jun 30, 2017 | -292,455.00 |
| Jun 30, 2017 | -292,455.00 |
| Mar 31, 2017 | -292,455.00 |
| Mar 31, 2017 | -292,455.00 |
| Dec 31, 2016 | -497,164.00 |
| Dec 31, 2016 | -497,164.00 |
| Sep 30, 2016 | 728,100.00 |
| Sep 30, 2016 | 728,100.00 |